Loading
Gemcitabine plus cisplatin has been the chemotherapy backbone for bile duct cancer since 2010 and is now given with immunotherapy.
Gemcitabine, a nucleoside analogue that terminates DNA chains, is combined with cisplatin, which crosslinks DNA, giving two complementary attacks on dividing cells. The doublet has been the chemotherapy backbone for advanced biliary tract cancer since ABC-02 (2010) showed overall survival of 11.7 versus 8.1 months against gemcitabine alone (HR 0.64), and it is given on days 1 and 8 of a 3-week cycle for up to 8 cycles. It is now the backbone of TOPAZ-1 with durvalumab (OS HR 0.76, 24-month OS 23.6% versus 11.5%) and KEYNOTE-966 with pembrolizumab (OS 12.7 versus 10.9 months), so most patients receive it with immunotherapy. Adding nab-paclitaxel (SWOG 1815) did not improve survival. Grade 3 to 4 neutropenia (25%) and fatigue are the main toxicities, and renal function and hearing need monitoring. For a newcomer, this is the standard two-drug chemotherapy for bile duct cancer.
Nucleoside analogue (gemcitabine) plus DNA crosslinker (cisplatin).
1.Gemcitabine + cisplatin slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia (grade 3-4) | - | 25% |
| Fatigue | - | 19% |
ABC-02. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
The tail of long survivors is the case for chemo-immunotherapy in gallbladder cancer, where the median gain is under two months. Who lands in that tail is still unknown; no biomarker in the trial predicts it.
The rationale for OPT-IN and GAIN in one place. Until OPT-IN reports in 2028 the neoadjuvant approach for incidental cancer remains a reasoned choice rather than a proven one.
Comprehensive genomic profiling at diagnosis is now justified for unfavourable cancer of unknown primary, with a switch to a matched drug after induction chemotherapy when an actionable target is found.
Together with JUPITER-02 and RATIONALE-309, this trial made PD-1 blockade plus gemcitabine-cisplatin the first-line standard for metastatic nasopharyngeal carcinoma.
The standard-of-care rows on the locoregionally advanced nasopharyngeal page follow this guideline.
PD-1 blockade with gemcitabine and cisplatin is the first-line standard for recurrent or metastatic nasopharyngeal carcinoma, and the first immunotherapy approved for this cancer in the United States.
It defines who a homologous recombination result should send to platinum: core-gene and biallelic carriers, germline or somatic, rather than any repair-gene variant.
Induction gemcitabine and cisplatin followed by chemoradiotherapy is the standard for locoregionally advanced nasopharyngeal carcinoma in endemic regions and in guidelines internationally.
Query for this drug: (TITLE:"Gemcitabine + cisplatin" OR ABSTRACT:"Gemcitabine + cisplatin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gemcitabine + cisplatin, not a curated reading list.
Shares Mucinous carcinoma of the gallbladder, Adenosquamous and squamous carcinoma of the gallbladder, Cystic duct carcinoma, Chemotherapy before the second operation for high-risk incidental gallbladder cancer.
Shares ACTICCA-1, A ctDNA residual disease-guided adjuvant trial after gallbladder cancer resection, Gallbladder adenocarcinoma, Incidental gallbladder cancer (found after cholecystectomy).
Shares ABC-12, Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo), DEBATE, NIFE (AIO-YMO HEP-0315).
Shares A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02), ABC-12, AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer, Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs).
Shares Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01), KEYNOTE-966, ACTICCA-1, TOPAZ-1.
Shares HERIZON-BTC-302, Gallbladder adenocarcinoma, SAFIR-ABC10, Extrahepatic cholangiocarcinoma (perihilar and distal).
Shares HERIZON-BTC-302, Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.
Shares Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study, ABC-02, TOPAZ-1, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.